Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy

In the near future, important translational questions of clinical relevance will be adressed by studies currently in progress. On the one hand, the role of PD-L1 expression must be further understood, after it was found to be relevant in the use of atezolizumab in first-line therapy of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartkopf, Andreas D., Müller, Volkmar, Wöckel, Achim, Lux, Michael P., Janni, Wolfgang, Ettl, Johannes, Belleville, Erik, Schütz, Florian, Fasching, Peter A., Kolberg, Hans-Christian, Welslau, Manfred, Overkamp, Friedrich, Taran, Florin-Andrei, Brucker, Sara Y., Wallwiener, Markus, Tesch, Hans, Fehm, Tanja N., Schneeweiss, Andreas, Lüftner, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924326/
https://www.ncbi.nlm.nih.gov/pubmed/31875860
http://dx.doi.org/10.1055/a-1039-4458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924326/
https://www.ncbi.nlm.nih.gov/pubmed/31875860
http://dx.doi.org/10.1055/a-1039-4458

Ejemplares similares